• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email
    SC 13G/A 1 p22-0088sc13ga.htm AETHLON MEDICAL, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Aethlon Medical, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001

    (Title of Class of Securities)
     

    00808Y307

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 00808Y30713GPage 2 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.68% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 00808Y30713GPage 3 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.68% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 00808Y30713GPage 4 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.68% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 00808Y30713GPage 5 of 9 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Aethlon Medical, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock underlying the Reported Warrants (as defined below) held by funds to which the Investment Manager serves as investment manager (the "Empery Funds").
       
      Reporting Individuals
       
      (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock underlying the Reported Warrants held by the Empery Funds.
       
      (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock underlying the Reported Warrants held by the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
       

    The address of the business office of each of the Reporting Persons is:

     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

         

     

    CUSIP No. 00808Y30713GPage 6 of 9 Pages

     

    Item 2(c). CITIZENSHIP:
       
      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      00808Y307

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    CUSIP No. 00808Y30713GPage 7 of 9 Pages

     

      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:    

     

    Item 4. OWNERSHIP.
       
      The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 15,397,299 shares of Common Stock issued and outstanding as of November 5, 2021, as represented in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2021 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”).
       
      The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
      Not applicable.

     

    CUSIP No. 00808Y30713GPage 8 of 9 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 00808Y30713GPage 9 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: January 13, 2022

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

    Get the next $AEMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    SEC Filings

    See more
    • Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/27/25 1:04:24 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Aethlon Medical Inc.

      10-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/26/25 5:10:22 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Inc. filed SEC Form 8-K: Other Events

      8-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/5/25 8:30:54 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Broenniman Edward G covered exercise/tax liability with 893 shares, decreasing direct ownership by 4% to 21,825 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:08 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Director Shah Chetan covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 8% to 19,993 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:05 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Director Gikakis Nicolas covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 8% to 20,004 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:06 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

      H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

      7/7/25 8:15:50 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      6/25/21 6:10:29 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

      HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

      6/1/21 8:48:18 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

       Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.  Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian

      6/26/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

      SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P

      6/20/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

      Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 mon

      6/18/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Financials

    Live finance-specific insights

    See more
    • Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

       Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.  Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian

      6/26/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

      SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P

      6/20/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

      Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a

      2/12/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

      SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

      1/13/22 10:30:14 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Aethlon Medical, Inc.

      SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

      6/15/21 10:01:32 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

      2/22/21 9:53:48 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care